Drugs / PHN-010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06457997 | Jul 2024 → Sep 2025 | cervical cancer, colorectal cancer, endometrial cancer, lung cancer +1 | Pheon Therapeutics | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PHN-010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06457997 ↗ |
| Modality | Other / unclassified | “PHN-010, a novel antibody-drug conjugate (ADC)” NCT06457997 ↗ |
| Route | Intravenous | “PHN-010 is administered intravenously.” NCT06457997 ↗ |